un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31.12.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.5 pts less than Nifty Microcap 250 and 10.4 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Samsrita Labs Limited reported nil revenue from operations across both standalone and consolidated results for the quarter and nine months ended 31 December 2025. Standalone loss for Q3 FY26 widened sharply to Rs 335.56 lakhs (from Rs 4.05 lakhs loss in the year-ago quarter), while the nine-month loss ballooned to Rs 856.72 lakhs (from Rs 17.25 lakhs). The spike in expenses was driven by a one-time write-off of Rs 3.26 crores worth of intangible assets under development, which the company said were no longer expected to generate future economic benefits due to technological obsolescence. On a consolidated basis, Q3 loss was Rs 293.94 lakhs, partly cushioned by the company's share of profits from two associates (Kris Biosciences and Qrops Advisory Services). The statutory auditor, MGR & Co, issued a limited review report with an emphasis-of-matter paragraph specifically flagging the write-off.
Negative for shareholders — the company posted zero operating revenue, deepening losses, and a large intangible-asset write-off, signalling weak core business activity. The emphasis-of-matter note from auditors adds caution, though the results remain a limited review (not a full audit). The stock may remain under pressure given the absence of any operational income.